{
  "main_header": {
    "sid": 890385,
    "name": "Guj. Terce Labs.",
    "stock_name": "Guj. Terce Labs.",
    "full_name": "Gujarat Terce Laboratories Ltd",
    "name_url": "stocks-analysis/guj-terce-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "47.90",
    "chg": 0.26,
    "chgp": "0.55%",
    "dir": 1,
    "prev_price": "47.64",
    "mcapval": "35.54 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524314,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE499G01013",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "8 ",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/guj-terce-labs-890385-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Gujarat Terce Laboratories Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gujarat-terce-laboratories-downgraded-to-sell-amid-mixed-technicals-and-weak-fundamentals-3747788",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GujaratTerceLab_mojoScore_3747788.png",
        "date": "2025-12-05 08:09:35",
        "description": "Gujarat Terce Laboratories has experienced a notable revision in its market evaluation, reflecting a complex interplay of technical indicators and fundamental financial data. While recent trading activity shows signs of stabilisation, underlying financial metrics continue to present challenges, prompting a nuanced reassessment of the company's investment profile."
      },
      {
        "title": "Why is Guj. Terce Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-guj-terce-labs-fallingrising-3747314",
        "imagepath": "",
        "date": "2025-12-05 01:03:32",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Price Momentum and Market Outperformance</strong></p>\n<p>The stock’s performance on 04-Dec was marked by a significant gap-up opening, with shares starting the day 7.45% higher than the previous close. Throughout the trading session, the stock reached an intraday high of ₹48, representing a 7.67% increase. This robust price action outpaced the sector by 6.57%, signalling strong relative strength within its industry group. Furthermore, Gujarat Terce Laboratories has been on a positive trajectory for two consecutive days, accumulating an 8.25% gain over this period. Such momentum indicates growing investor confidence and a possible shift in market sentiment towards the stock.</p>\n<p><strong>Rising Investor Participation and Liquidity</strong></p>\n<p>One of the key drivers behind the..."
      },
      {
        "title": "How has been the historical performance of Guj. Terce Labs.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-guj-terce-labs-3747111",
        "imagepath": "",
        "date": "2025-12-04 22:49:00",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Over the three fiscal years ending March 2021, Guj. Terce Labs. witnessed a notable decline in net sales, falling from ₹37.54 crores in March 2020 to ₹25.18 crores in March 2021. This represents a significant contraction of approximately 33%, reversing the growth seen in the previous year when sales had increased from ₹31.03 crores in March 2019 to ₹37.54 crores in March 2020. The absence of other operating income throughout these years indicates that the company’s revenue streams are solely dependent on its core operations.</p>\n<p>Cost management has been a mixed bag. Raw material costs and purchase of finished goods decreased in line with lower sales, but employee costs remained relatively high, only marginally reduced from ₹15.13 crores in ..."
      },
      {
        "title": "Is Guj. Terce Labs. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-guj-terce-labs-overvalued-or-undervalued-3709851",
        "imagepath": "",
        "date": "2025-11-18 08:22:54",
        "description": "As of 17 November 2025, the valuation grade for Guj. Terce Labs. has moved from expensive to very expensive. This indicates a significant deterioration in its valuation outlook, suggesting that the company is overvalued. The key ratios highlight this concern, with a PE ratio of -32.23, a Price to Book Value of 4.39, and an EV to EBITDA of 7.59, all of which signal potential overvaluation when compared to industry norms.\n\nIn comparison to its peers, Guj. Terce Labs. stands out unfavorably; for instance, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Divi's Lab shows a PE of 69.78 and an EV to EBITDA of 52.44. These comparisons further reinforce the notion that Guj. Terce Labs. is not only overvalued but also lagging behind its competitors in terms of financial performance. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -47.76%, contra..."
      },
      {
        "title": "How has been the historical performance of Guj. Terce Labs.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-guj-terce-labs-3683702",
        "imagepath": "",
        "date": "2025-11-09 22:47:36",
        "description": "Answer:\nThe historical performance of Guj. Terce Labs shows a decline in net sales and profitability over the past three years, culminating in a loss in the most recent fiscal year.\n\nBreakdown:\nGuj. Terce Labs reported net sales of 25.18 Cr in March 2021, a significant decrease from 37.54 Cr in March 2020 and 31.03 Cr in March 2019. The total operating income mirrored this trend, remaining at 25.18 Cr in March 2021, down from 37.54 Cr in March 2020. The company's total expenditure, excluding depreciation, was 27.94 Cr in March 2021, which also decreased from 36.86 Cr in March 2020. This led to an operating profit (PBDIT) of -1.96 Cr in March 2021, contrasting with a profit of 0.97 Cr in March 2020 and 0.80 Cr in March 2019. Consequently, the profit before tax fell to -2.53 Cr in March 2021, down from 0.44 Cr in March 2020. The profit after tax also reflected this downturn, resulting in a loss of 2.52 Cr in ..."
      },
      {
        "title": "Are Guj. Terce Labs. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-guj-terce-labs-latest-results-good-or-bad-3683316",
        "imagepath": "",
        "date": "2025-11-09 19:14:31",
        "description": "Gujarat Terce Laboratories' latest financial results for Q2 FY26 reveal significant operational challenges. The company reported net sales of ₹10.13 crores, reflecting marginal growth of 1.91% sequentially, while year-on-year performance remained essentially flat at 0.20%. However, the most concerning aspect was the sharp contraction in operating profit margins, which fell to 5.33% from 16.40% in the previous quarter, indicating severe operational stress.\n\nNet profit for the quarter was ₹0.45 crores, which represents a substantial decline of 71.88% compared to the previous quarter. This decline in profitability highlights difficulties in cost management, particularly as employee costs rose significantly, consuming nearly 39% of revenues. The company's return on equity (ROE) has also been notably weak, with a recent figure of -15.34%, further underscoring the operational distress.\n\nDespite the company mainta..."
      },
      {
        "title": "Gujarat Terce Laboratories Q2 FY26: Profit Plunge Raises Serious Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/gujarat-terce-laboratories-q2-fy26-profit-plunge-raises-serious-concerns-3682515",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GujaratTerceLab_quaterlyResult_3682515.png",
        "date": "2025-11-08 18:02:17",
        "description": "Gujarat Terce Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹32.00 crores, reported deeply concerning quarterly results for Q2 FY26 (Jul-Sep'25), with net profit plummeting 71.88% quarter-on-quarter to ₹0.45 crores from ₹1.60 crores in Q1 FY26. The stock, currently trading at ₹45.98, has collapsed 45.25% over the past year, significantly underperforming both the broader market and its pharmaceutical sector peers."
      },
      {
        "title": "Why is Guj. Terce Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-guj-terce-labs-fallingrising-3676862",
        "imagepath": "",
        "date": "2025-11-06 22:31:09",
        "description": "As of 06-Nov, Gujarat Terce Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 44.15, which reflects a decrease of Rs 1.71 or 3.73%. The stock has been underperforming, having lost 5.07% over the last two days and is trading below all key moving averages, indicating a bearish trend. Additionally, the stock's performance today has underperformed its sector by 2.96%. Over the past week, the stock has decreased by 6.36%, and year-to-date, it has plummeted by 47.94%, showcasing significant underperformance compared to the Sensex, which has gained 6.62% during the same period. There is also a notable decline in investor participation, with delivery volume dropping by 83.32% against the 5-day average, suggesting reduced interest in the stock.\n\nBroader Market Context: In the context of the broader market, Gujarat Terce Laboratories Ltd's recent performance contrasts sharply with the Sen..."
      },
      {
        "title": "Why is Guj. Terce Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-guj-terce-labs-fallingrising-3659723",
        "imagepath": "",
        "date": "2025-10-30 22:31:44",
        "description": "As of 30-Oct, Gujarat Terce Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 47.15, which reflects a decrease of Rs 1.45 or 2.98%. The stock has underperformed its sector by 2.64% today and opened with a significant loss of 6.69%. It reached an intraday low of Rs 45.12, indicating a drop of 7.16%. In terms of performance over different periods, the stock has seen a 10.67% decline over the past week, while it has gained 3.65% over the past month. However, it has suffered a substantial year-to-date decline of 44.40%. Despite this, there has been a notable increase in investor participation, with delivery volume rising by 40.33% against the 5-day average, suggesting some interest in the stock despite its recent downturn.\n\nBroader Market Context: In comparison to the benchmark Sensex, which has only decreased by 0.18% over the past week, Gujarat Terce Laboratories Ltd's performance..."
      }
    ],
    "total": 168,
    "sid": "890385",
    "stock_news_url": "https://www.marketsmojo.com/news/gujarat-terce-laboratories-890385"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "10-Nov-2025",
      "details": "Extracts of Newspaper Publication in prescribed format of the Unaudited Standalone Financial Results for the Second quarter and half year ended 30 September 2025.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
      "datetime": "08-Nov-2025",
      "details": "Pursuant to Regulation 30 of the SEBI (Listng Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith Investor Presentation for the quarter and half year ended 30 September 2025.",
      "source": "BSE"
    },
    {
      "caption": "Unaudited Standalone Financial Results Of The Company Forthe Second Quarter And Half Year Ended 30 September2025 - Regulations 30 And 33 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "08-Nov-2025",
      "details": "Detailes disclosure is attached.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Gujarat Terce Laboratories Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals

2025-12-05 08:09:35

Gujarat Terce Laboratories has experienced a notable revision in its market evaluation, reflecting a complex interplay of technical indicators and fundamental financial data. While recent trading activity shows signs of stabilisation, underlying financial metrics continue to present challenges, prompting a nuanced reassessment of the company's investment profile.

Read More

Why is Guj. Terce Labs. falling/rising?

2025-12-05 01:03:32

Short-Term Price Momentum and Market Outperformance

The stock’s performance on 04-Dec was marked by a significant gap-up opening, with shares starting the day 7.45% higher than the previous close. Throughout the trading session, the stock reached an intraday high of ₹48, representing a 7.67% increase. This robust price action outpaced the sector by 6.57%, signalling strong relative strength within its industry group. Furthermore, Gujarat Terce Laboratories has been on a positive trajectory for two consecutive days, accumulating an 8.25% gain over this period. Such momentum indicates growing investor confidence and a possible shift in market sentiment towards the stock.

Rising Investor Participation and Liquidity

One of the key drivers behind the...

Read More

How has been the historical performance of Guj. Terce Labs.?

2025-12-04 22:49:00

Revenue and Profitability Trends

Over the three fiscal years ending March 2021, Guj. Terce Labs. witnessed a notable decline in net sales, falling from ₹37.54 crores in March 2020 to ₹25.18 crores in March 2021. This represents a significant contraction of approximately 33%, reversing the growth seen in the previous year when sales had increased from ₹31.03 crores in March 2019 to ₹37.54 crores in March 2020. The absence of other operating income throughout these years indicates that the company’s revenue streams are solely dependent on its core operations.

Cost management has been a mixed bag. Raw material costs and purchase of finished goods decreased in line with lower sales, but employee costs remained relatively high, only marginally reduced from ₹15.13 crores in ...

Read More

Is Guj. Terce Labs. overvalued or undervalued?

2025-11-18 08:22:54

As of 17 November 2025, the valuation grade for Guj. Terce Labs. has moved from expensive to very expensive. This indicates a significant deterioration in its valuation outlook, suggesting that the company is overvalued. The key ratios highlight this concern, with a PE ratio of -32.23, a Price to Book Value of 4.39, and an EV to EBITDA of 7.59, all of which signal potential overvaluation when compared to industry norms. In comparison to its peers, Guj. Terce Labs. stands out unfavorably; for instance, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Divi's Lab shows a PE of 69.78 and an EV to EBITDA of 52.44. These comparisons further reinforce the notion that Guj. Terce Labs. is not only overvalued but also lagging behind its competitors in terms of financial performance. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -47.76%, contra...

Read More

How has been the historical performance of Guj. Terce Labs.?

2025-11-09 22:47:36

Answer: The historical performance of Guj. Terce Labs shows a decline in net sales and profitability over the past three years, culminating in a loss in the most recent fiscal year. Breakdown: Guj. Terce Labs reported net sales of 25.18 Cr in March 2021, a significant decrease from 37.54 Cr in March 2020 and 31.03 Cr in March 2019. The total operating income mirrored this trend, remaining at 25.18 Cr in March 2021, down from 37.54 Cr in March 2020. The company's total expenditure, excluding depreciation, was 27.94 Cr in March 2021, which also decreased from 36.86 Cr in March 2020. This led to an operating profit (PBDIT) of -1.96 Cr in March 2021, contrasting with a profit of 0.97 Cr in March 2020 and 0.80 Cr in March 2019. Consequently, the profit before tax fell to -2.53 Cr in March 2021, down from 0.44 Cr in March 2020. The profit after tax also reflected this downturn, resulting in a loss of 2.52 Cr in ...

Read More

Are Guj. Terce Labs. latest results good or bad?

2025-11-09 19:14:31

Gujarat Terce Laboratories' latest financial results for Q2 FY26 reveal significant operational challenges. The company reported net sales of ₹10.13 crores, reflecting marginal growth of 1.91% sequentially, while year-on-year performance remained essentially flat at 0.20%. However, the most concerning aspect was the sharp contraction in operating profit margins, which fell to 5.33% from 16.40% in the previous quarter, indicating severe operational stress. Net profit for the quarter was ₹0.45 crores, which represents a substantial decline of 71.88% compared to the previous quarter. This decline in profitability highlights difficulties in cost management, particularly as employee costs rose significantly, consuming nearly 39% of revenues. The company's return on equity (ROE) has also been notably weak, with a recent figure of -15.34%, further underscoring the operational distress. Despite the company mainta...

Read More

Gujarat Terce Laboratories Q2 FY26: Profit Plunge Raises Serious Concerns

2025-11-08 18:02:17

Gujarat Terce Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹32.00 crores, reported deeply concerning quarterly results for Q2 FY26 (Jul-Sep'25), with net profit plummeting 71.88% quarter-on-quarter to ₹0.45 crores from ₹1.60 crores in Q1 FY26. The stock, currently trading at ₹45.98, has collapsed 45.25% over the past year, significantly underperforming both the broader market and its pharmaceutical sector peers.

Read More

Why is Guj. Terce Labs. falling/rising?

2025-11-06 22:31:09

As of 06-Nov, Gujarat Terce Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 44.15, which reflects a decrease of Rs 1.71 or 3.73%. The stock has been underperforming, having lost 5.07% over the last two days and is trading below all key moving averages, indicating a bearish trend. Additionally, the stock's performance today has underperformed its sector by 2.96%. Over the past week, the stock has decreased by 6.36%, and year-to-date, it has plummeted by 47.94%, showcasing significant underperformance compared to the Sensex, which has gained 6.62% during the same period. There is also a notable decline in investor participation, with delivery volume dropping by 83.32% against the 5-day average, suggesting reduced interest in the stock. Broader Market Context: In the context of the broader market, Gujarat Terce Laboratories Ltd's recent performance contrasts sharply with the Sen...

Read More

Why is Guj. Terce Labs. falling/rising?

2025-10-30 22:31:44

As of 30-Oct, Gujarat Terce Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 47.15, which reflects a decrease of Rs 1.45 or 2.98%. The stock has underperformed its sector by 2.64% today and opened with a significant loss of 6.69%. It reached an intraday low of Rs 45.12, indicating a drop of 7.16%. In terms of performance over different periods, the stock has seen a 10.67% decline over the past week, while it has gained 3.65% over the past month. However, it has suffered a substantial year-to-date decline of 44.40%. Despite this, there has been a notable increase in investor participation, with delivery volume rising by 40.33% against the 5-day average, suggesting some interest in the stock despite its recent downturn. Broader Market Context: In comparison to the benchmark Sensex, which has only decreased by 0.18% over the past week, Gujarat Terce Laboratories Ltd's performance...

Read More

View All News